These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 24170753)

  • 1. Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern?
    Monnier L; Colette C; Dejager S; Owens D
    Diabetes Care; 2013 Dec; 36(12):4057-62. PubMed ID: 24170753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency and severity of the dawn phenomenon in type 2 diabetes: relationship to age.
    Monnier L; Colette C; Sardinoux M; Baptista G; Regnier-Zerbib A; Owens D
    Diabetes Care; 2012 Dec; 35(12):2597-9. PubMed ID: 22991448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comment on Monnier et al. Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern? Diabetes Care 2013;36:4057-4062.
    Carr RD; Alexander CM
    Diabetes Care; 2014 Jul; 37(7):e161-2. PubMed ID: 24963116
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to comment on Monnier et al. Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern? Diabetes Care 2013;36:4057-4062.
    Monnier L; Colette C; Dejager S; Owens D
    Diabetes Care; 2014 Jul; 37(7):e163. PubMed ID: 24963117
    [No Abstract]   [Full Text] [Related]  

  • 5. The impact of dusk phenomenon on total glucose exposure in Chinese people with type 2 diabetes.
    Huang Y; Xu Y; Qiu J; Jiang C; Tan W; Tao X; Gu Q; Sun J
    Medicine (Baltimore); 2021 Apr; 100(13):e25298. PubMed ID: 33787619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dawn phenomenon in type 2 diabetes: how to assess it in clinical practice?
    Monnier L; Colette C; Dejager S; Owens D
    Diabetes Metab; 2015 Apr; 41(2):132-7. PubMed ID: 25457475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes.
    Porcellati F; Lucidi P; Bolli GB; Fanelli CG
    Diabetes Care; 2013 Dec; 36(12):3860-2. PubMed ID: 24265365
    [No Abstract]   [Full Text] [Related]  

  • 8. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
    Turner RC; Cull CA; Frighi V; Holman RR
    JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe dawn phenomenon predicts long-term risk of all-cause mortality in patients with type 2 diabetes.
    Cai J; Peng P; Lu J; Shen Y; Wang C; Mo Y; Lu W; Zhu W; Xia T; Zhou J
    Diabetes Metab Res Rev; 2024 May; 40(4):e3813. PubMed ID: 38767128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of the dawn phenomenon in type 2 diabetes: implications for diabetes therapy.
    Carroll MF; Hardy KJ; Burge MR; Schade DS
    Diabetes Technol Ther; 2002; 4(5):595-605. PubMed ID: 12450440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HbA1c levels are better predicted by prebreakfast than postbreakfast blood glucose self-analyses in type 2 diabetes. Influence of duration of diabetes and mode of treatment.
    Relimpio F; Guerrero R; Martínez-Brocca MA
    Acta Diabetol; 2007 Jun; 44(2):55-9. PubMed ID: 17530467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical factors associated with absolute and relative measures of glycemic variability determined by continuous glucose monitoring: an analysis of 480 subjects.
    Jin SM; Kim TH; Bae JC; Hur KY; Lee MS; Lee MK; Kim JH
    Diabetes Res Clin Pract; 2014 May; 104(2):266-72. PubMed ID: 24630619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring.
    Hay LC; Wilmshurst EG; Fulcher G
    Diabetes Technol Ther; 2003; 5(1):19-26. PubMed ID: 12725703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of flash glucose monitoring on glycated hemoglobin in type 2 diabetes managed with basal insulin in Canada: A retrospective real-world chart review study.
    Elliott T; Beca S; Beharry R; Tsoukas MA; Zarruk A; Abitbol A
    Diab Vasc Dis Res; 2021; 18(4):14791641211021374. PubMed ID: 34275385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Mild dysglycemia" in type 2 diabetes: to be neglected or not?
    Monnier L; Colette C; Dejager S; Owens DR
    J Diabetes Complications; 2015 Apr; 29(3):451-8. PubMed ID: 25572605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoglycemia in People with Type 2 Diabetes and CKD.
    Ahmad I; Zelnick LR; Batacchi Z; Robinson N; Dighe A; Manski-Nankervis JE; Furler J; O'Neal DN; Little R; Trence D; Hirsch IB; Bansal N; de Boer IH
    Clin J Am Soc Nephrol; 2019 Jun; 14(6):844-853. PubMed ID: 30996047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Composite Glycemic Indices: A Comparison of the Comprehensive Glucose Pentagon Across Diabetes Types and HbA1c Levels.
    Rama Chandran S; A Vigersky R; Thomas A; Lim LL; Ratnasingam J; Tan A; S L Gardner D
    Diabetes Technol Ther; 2020 Feb; 22(2):103-111. PubMed ID: 31502876
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of insulin initiation on glycaemic variability and glucose profiles in a primary healthcare Type 2 diabetes cohort: analysis of continuous glucose monitoring data from the INITIATION study.
    Manski-Nankervis J; Yates CJ; Blackberry I; Furler J; Ginnivan L; Cohen N; Jenkins A; Vasanthakumar S; Gorelik A; Young D; Best J; O'Neal D
    Diabet Med; 2016 Jun; 33(6):803-11. PubMed ID: 26435033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction in Glycated Hemoglobin and Daily Insulin Dose Alongside Circadian Clock Upregulation in Patients With Type 2 Diabetes Consuming a Three-Meal Diet: A Randomized Clinical Trial.
    Jakubowicz D; Landau Z; Tsameret S; Wainstein J; Raz I; Ahren B; Chapnik N; Barnea M; Ganz T; Menaged M; Mor N; Bar-Dayan Y; Froy O
    Diabetes Care; 2019 Dec; 42(12):2171-2180. PubMed ID: 31548244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.